Project title: Multicenter, randomized, double-blind, placebocontrolledstudy to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS).
Project title: Multicenter, randomized, double-blind, placebocontrolledstudy to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS).
Project financing: 16 880 726,88 PLN (including financing for UMED: 3 611 233,02 PLN), financed by the Medical Research Agency (ABM)
The aim of the project is to evaluate the efficacy, tolerability and safety of rapamycin as add-on therapy to antiepileptic drugs in patients with drug-resistant epilepsy associated with tuberous sclerosis. In addition, the RaRE-TS study will prospectively analyse molecular, electrophysiological and neuroimaging biomarkers of epileptogenesis and oncogenesis.
The project is being carried out in a consortium with the Institute – Pomnik “Children’s Health Centre” as leader and Medical University of Lodz as partner.
Consortium composed of:
prof. Katarzyna Kotulska-Jóźwiak, MD, PhD